id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-N-0191-0005,FDA,FDA-2004-N-0191,Product Jurisdiction: Correction,Proposed Rule,Correction,2018-06-07T04:00:00Z,2018,6,2018-06-07T04:00:00Z,2018-07-17T03:59:59Z,2025-04-11T18:29:27Z,2018-12201,0,0,090000648336367b
FDA-2004-N-0191-0004,FDA,FDA-2004-N-0191,Product Jurisdiction,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2018-05-15T04:00:00Z,2018,5,2018-05-15T04:00:00Z,2018-07-17T03:59:59Z,2025-04-11T18:28:38Z,2018-10321,0,0,09000064832686f5
FDA-2004-N-0191-0003,FDA,FDA-2004-N-0191,Definition of Primary Mode of Action of a Combination Product,Rule,Final Rule,2005-08-25T04:00:00Z,2005,8,,,2025-04-22T11:55:50Z,05-16527,0,0,09000064804709ac
FDA-2004-N-0191-0002,FDA,FDA-2004-N-0191,Definition of Primary Mode of Action of a Combination Product,Proposed Rule,Extension of Comment Period,2004-06-25T04:00:00Z,2004,6,2004-06-24T04:00:00Z,2004-08-21T03:59:59Z,2025-04-22T11:40:20Z,04-14265,0,0,0900006480470985
FDA-2004-N-0191-0001,FDA,FDA-2004-N-0191,Definition of Primary Mode of Action of a Combination Product,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2004-05-12T00:00:00Z,2004,5,2004-05-07T00:00:00Z,2004-07-07T03:59:59Z,2025-05-09T04:34:42Z,04 10447,0,0,0900006480470980